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 Th e development of biopharmaceuticals 
such as erythropoiesis-stimulating agents 
(ESAs) has been a major therapeutic 
achievement that has increased our ability 
to treat many diseases previously thought 
to be incurable. A biopharmaceutical is 
defi ned as  ‘ a medicine whose active sub-
stance is made by or derived from a living 
organism. ’ 1 Th ere are more than 100 exist-
ing biopharmaceutical agents and over 
400 new ones under development. A 
 ‘ biosimilar ’ (in Europe), or  ‘ follow-on bio-
logic ’ agent (in the United States), is  ‘ a 
medicine which is similar to a biological 
medicine that has already been author-
ized ’ and whose patent has typically 
expired. 1 It is oft en referred to as a  ‘ generic ’ 
biopharmaceutical, but, unlike the generic 
version of a chemical agent, there is no 
guarantee that a biosimilar agent is identi-
cal to the reference agent, as the structure 
of the large proteins involved cannot be 
unequivocally determined. Th e driving 
force behind the development of biosimi-
lars is primarily fi nancial, analogous to the 
cost savings arising from the use of generic 
or lower-cost  ‘ me too ’ versions of branded 
chemical therapeutic agents. In the case of 
generic chemical competitors, the market 
usually welcomes the opportunity for cost 
savings even though data supporting 
equivalence to the reference agent may be 
weak. The complexities related to the 
manufacturing, packaging, storage, and 
shipping of biopharmaceutical agents 
make their biosimilar competitors much 
more vulnerable to efficacy and safety 
issues, so greater vigilance is required to 
assure that biosimilars undergo adequate 
pre- and postmarketing scrutiny to assure 
their therapeutic value. 
 Praditpornsilpa  et al. 2 (this issue) 
describe the experience in Th ailand with 
biosimilar ESAs. Epoetin-alfa was licensed 
in Th ailand in 1990 and epoetin-beta in 
1998. The first biosimilar epoetin-alfa 
became available in 1997 in Th ailand, and, 
as of 2009, 14 biosimilar ESAs were 
licensed in Thailand, manufactured in 
Argentina, China, South Korea, and India. 
Concomitant with the increased penetra-
tion of biosimilar ESAs in the Th ai mar-
ket, the authors noted an alarming 
increase in the prevalence of pure red-cell 
aplasia (PRCA) and sought to more sys-
tematically diagnose the disorder and 
characterize the epidemic. Th ey were able 
to confi rm that 23 of 30 patients referred 
because of loss of ESA effi  cacy had anti-
bodies to erythropoietin, consistent with 
PRCA. All of these patients received the 
biosimilar ESA subcutaneously, confi rm-
ing previous observations that the interac-
tion between an ill-defi ned alteration in 
the erythropoietin molecule and subcuta-
neous injection of the agent is a prerequi-
site for the development of PRCA. 
 PRCA is a relatively rare condition that 
leads to progressive, severe anemia. It has 
been associated with a congenital disorder 
known as Diamond – Blackfan syndrome 
and has been associated with acquired 
disorders such as thymoma, systemic 
lupus, or viral infection. 3 Bone marrow 
examination in aff ected patients reveals an 
almost complete absence of red-cell pre-
cursors with normal numbers of white-
cell and platelet precursors. The 
reticulocyte count is extremely low. A 
number of case reports of an antibody-
mediated form of PRCA associated with 
ESA therapy started to appear in the mid-
1990s, but this complication did not 
receive much attention until an epidemic 
of ESA-associated PRCA occurred 
between 1998 and 2002. In 1998, Johnson 
 & Johnson, the manufacturer of Eprex 
(a brand of epoetin-alfa), changed the sta-
bilizing agent from human serum albu-
min to polysorbate 80 and glycine. It is 
hypothesized that the polysorbate 80 
interacted with leachates from the 
uncoated rubber stoppers in the Eprex-
prefilled syringes to induce increased 
immunogenicity of the agent and result in 
the increased incidence of PRCA, but only 
when the substance was administered 
subcutaneously. Once the problem was 
identifi ed, Johnson  & Johnson coated the 
rubber stoppers in the prefi lled syringes 
with latex, and the PRCA epidemic sub-
sided. Th e aff ected patients demonstrated 
neutralizing antibodies to epoetin that 
crossreact with endogenous erythropoi-
etin. Since Eprex is not marketed in the 
United States, patients there were not 
affected by this PRCA epidemic. 
In December 2002, health authorities in 
Europe formally contraindicated sub-
cutaneous administration of Eprex for 
patients with chronic kidney disease. 4 
There have been case reports of PRCA 
occurring in patients who have received dar-
bepoetin, the Epogen form of epoetin-alfa, 
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and epoetin-beta, but 91 % of 191 antibody-
mediated PRCA cases worldwide reported 
in 2004 were associated with Eprex. 5 A 
timeline of major events regarding ESA-
associated PRCA is shown in  Figure 1 . 
 As of 2009, biosimilar, non-patented 
ESAs were available in many countries of 
Asia, South and Central America, and 
Africa. 6 Th ese agents are much less costly 
than patented ESAs, and their use allows 
countries with tight health-care budgets 
to off er ESA therapy to more patients. Th e 
subcutaneous administration of short-act-
ing ESAs provides even greater cost sav-
ings, as a smaller dose can be used to 
achieve the same target hemoglobin level 
as compared with intravenous adminis-
tration. 7 Praditpornsilpa  et al. report 23 
cases of ESA-related PRCA among an esti-
mated 59,900 patients at risk, for an inci-
dence rate of 1:2068. 2 To put this into 
perspective, Macdougall 8 noted that the 
incidence of ESA-related PRCA based on 
a review of the subject by Rossert  et al. 9 is 
in the order of 1:10,000 patients and com-
pares favorably with the 1:5000 risk of 
developing a life-threatening reaction to 
the administration of penicillin.  ‘ It seems 
unlikely that the incidence of biosimilar-
induced PRCA would ever approach this 
level. ’ 8 Macdougall puts his faith in the 
fact that  ‘ the very stringent regulations 
imposed by the EMEA [European Agency 
for the Evaluation of Medicinal Products, 
the European Union ’ s counterpart to the 
medication-review activities conducted 
by the Food and Drug Administration 
in the United States] on biosimilar pro-
duction mean that the chances of  inducing 
a more immunogenic product are prob-
ably very small. ’ 8 Th is is known as phar-
macovigilance, which is a responsibility 
shared among the pharmaceutical indus-
try, pharmacists, and physicians, with 
appropriately informed and educated 
patients. Th e temptation for hard-pressed 
health-care economies to use lower-cost 
biosimilar therapeutic agents must be bal-
anced by a system to ensure that physi-
cians, pharmacists, and patients truly 
understand the complex arguments and 
decisions that apply to this new and chal-
lenging area. An ESA-associated PRCA 
incidence rate of 1:2068 in Th ailand is 
unacceptable, and the Food and Drug 
Administration of Th ailand responded 
appropriately to establish a prospective 
immunogenicity surveillance registry of 
ESAs with subcutaneous exposure to esti-
mate the incidence of ESA-associated 
PRCA and to evaluate the effi  cacy of the 
currently available ESA products in that 
country. Given the magnitude of the safety 
issues associated with biosimilar ESA 
administration, Praditpornsilpa  et al. 2 
appropriately propose that these agents 
not be licensed through the conventional 
generic paradigm, which mainly focuses 
on bioequivalence, but that pre- and post-
marketing comparisons with the reference 
product be performed on biosimilar 
agents to assure their safety and effi  cacy. 
The authors note that data from pre-
licensing studies are usually too limited to 
identify all potential adverse eff ects and 
recommend that pharmacovigilance and 
risk management plans be submitted by the 
manufacturer as part of the evaluation. 2 
 Th e response of Th ailand to their epi-
demic of ESA-associated PRCA should 
serve as a model for other economies, 
including in those parts of the world 
where biosimilars are already used exten-
sively and those, such as the European 
Union, where increased use of biosimilars 
is anticipated. In 2005, in the wake of the 
Eprex-associated PRCA epidemic, Schelle-
kens 10 predicted the recurrence of a PRCA 
epidemic with biosimilar ESAs and 
strongly recommended the establishment 
of stringent country-specifi c approval and 
pharmacovigilance protocols by the 
EMEA, the US Food and Drug Adminis-
tration, and comparable agencies through-
out the world. Th ese would include newly 
developed or improved methods for anal-
ysis of product characteristics, algorithms 
for predicting immunogenicity (which 
may have a genetic predisposition), assays 
for measuring patients ’ immune response, 
and improved production methods. 
 Fortunately, antibody-mediated PRCA, 
although serious, is not usually fatal and 
generally resolves aft er withdrawal of the 
off ending ESA, immunosuppressive ther-
apy (corticosteroids, cyclophosphamide, 
cyclosporine, mycophenolate, and rituxi-
mab have all been used successfully), and 
multiple transfusions until endogenous 
red blood cell production resumes. Pegi-
nesatide (Hematide), a synthetic, peptide-
based erythropoietin receptor agonist 
with no homology to native erythropoi-
etin, has been shown to be eff ective in the 
treatment of 13 out of 14 patients with 
PRCA due to anti-erythropoietin antibod-
ies. 11 The development of synthetic 
replacements for biopharmaceutical 
agents holds promise for decreasing the 
production of autoantibodies against a 
biologic agent that crossreact with the 
native protein. However, given the inevi-
table possibility of unexpected conse-
quences when therapeutic agents try to 
 ‘ fool Mother Nature, ’ a strong pharma-
covigilance program for synthetic agents 
is recommended as well. 
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 Figure 1  |  Timeline of ESA-associated PRCA. EDTA, European Dialysis and Transplant Association; 
ERA, European Renal Association; ESA, erythropoiesis-stimulating agent; PRCA, pure red-cell 
aplasia; s.c., subcutaneous. 
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 Phosphate is essential in several crucial 
biological processes, including cellular 
energy metabolism, nucleic acid synthe-
sis, cell signaling, energy metabolism, and 
bone mineralization. Alterations in serum 
phosphate are associated with various 
pathological eff ects. Hypophosphatemia 
is common in rickets, osteomalacia, and 
other diseases, and hyperphosphatemia 
in chronic kidney disease has been dem-
onstrated to cause increased risk of car-
diovascular morbidity and mortality. 
More over, elevated phosphate concentra-
tions in subjects with normal kidney 
function are also associated with 
increased cardiovascular risk and mortal-
ity. 1 Th erefore it is important to identify 
the mechanisms involved in phosphate 
homeostasis. Phosphate balance is coor-
dinated by a complex process involving 
various organs and tissues, including the 
intestine, kidney, parathyroid gland, and 
bone as well as the vitamin D system and 
phosphatonins. Among the organs, the 
kidney has a key function in phosphate 
metabolism due to its ability to excrete 
phosphate and to control bone and min-
eral metabolism through the activation of 
vitamin D. 
 Phosphate transport in the small intestine 
and renal tubules is mediated mainly by 
three type II sodium – phosphate cotrans-
porters: NaPi-2a (SLC34A1), NaPi-2b 
(SLC34A2), and NaPi-2c (SLC34A3). NaPi-
2a is commonly expressed in the apical 
brush border membrane of the renal proxi-
mal tubule (highest in S1 segments and 
gradually decreasing toward S3 segments), 
and it is responsible for most of the renal 
phosphate reabsorption. In contrast, 
NaPi-2c protein is detected in S1 and S2 
and is absent in S3 segments. Th is trans-
porter has been associated with growth, 
as its abundance is at its maximum aft er 
weaning and decreases in the adult. Both 
NaPi-2a and NaPi-2c transport divalent 
phosphate ions (HPO 4   2 −   ), but with diff er-
ent stoichiometries. Th ree Na   +   ions are 
transported together with one HPO 4   2 −  
ion by NaPi-2a, whereas NaPi-2c exhibits 
a 2Na   +   / HPO 4   2 −   stoichiometry. Th erefore, 
transport by NaPi-2a is electrogenic, 
whereas transport by NaPi-2c is elec-
troneutral ( Figure 1 ). 2 NaPi-2b is mostly 
loca lized in the small intestine and is sen-
sitive to vitamin D. NaPi-2b has a low 
affi  nity for phosphate, and patients with 
NaPi-2b-inactivating mutations do not 
exhibit reduced serum phosphate levels, 
which would be expected in the case of 
the lack of a key transporter. However, 
studies in a conditional NaPi-2b-null 
mouse model demonstrated that deletion 
of NaPi-2b resulted in an increase in the 
expression of NaPi-2a in the renal proximal 
tubule and serum phosphate concentra-
tions remained normal, most likely owing 
to compensatory renal reabsorption. 3 
Intestinal phosphate absorption may have 
an eff ect on renal phosphate handling, 
perhaps, as recently suggested, by secre-
tion of peptides derived from the intes-
tine. 4 Recently, it was reported that mice 
knockout for both NaPi-2a and NaPi-2c, 
while showing severe hypophosphatemia, 
still had some renal phosphate reabsorp-
tion. 5 Th ese results imply the involvement 
of other secondary active phosphate trans-
porters along the nephron. Recent fi nd-
ings suggest that Pit-2, so far regarded as 
a ubiquitously expressed housekeeping 
phosphate transporter, is a new mediator 
of phosphate reabsorption in the proximal 
tubule, but with a diff erent adaptive time 
course than NaPi-2a and NaPi-2c. 6 
 The reabsorption of phosphate by 
the intestine and kidney is controlled by 
various hormones and peptides, including 
vitamin D, parathyroid hormone, and the 
phosphatonins, such as fi broblast growth 
factor 23, which act to increase intestinal 
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